Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus NAFCILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus NAFCILLIN SODIUM.
BICILLIN vs NAFCILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic